170 related articles for article (PubMed ID: 16337744)
1. Cyclooxygenase-2 in hepatocellular carcinoma.
Wu T
Cancer Treat Rev; 2006 Feb; 32(1):28-44. PubMed ID: 16337744
[TBL] [Abstract][Full Text] [Related]
2. Aberrant iNOS signaling is under genetic control in rodent liver cancer and potentially prognostic for the human disease.
Calvisi DF; Pinna F; Ladu S; Pellegrino R; Muroni MR; Simile MM; Frau M; Tomasi ML; De Miglio MR; Seddaiu MA; Daino L; Sanna V; Feo F; Pascale RM
Carcinogenesis; 2008 Aug; 29(8):1639-47. PubMed ID: 18579559
[TBL] [Abstract][Full Text] [Related]
3. New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system.
Berasain C; Castillo J; Prieto J; Avila MA
Liver Int; 2007 Mar; 27(2):174-85. PubMed ID: 17311611
[TBL] [Abstract][Full Text] [Related]
4. COX-2 expression in hepatocellular carcinoma is an initiation event; while EGF receptor expression with downstream pathway activation is a prognostic predictor of survival.
Foster J; Black J; LeVea C; Khoury T; Kuvshinoff B; Javle M; Gibbs JF
Ann Surg Oncol; 2007 Feb; 14(2):752-8. PubMed ID: 17146741
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of anti-proliferative effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on human liver cancer cells.
Nagahara T; Okano J; Murawaki Y
Oncol Rep; 2007 Nov; 18(5):1281-90. PubMed ID: 17914586
[TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenase-2 and prostaglandin signaling in cholangiocarcinoma.
Wu T
Biochim Biophys Acta; 2005 Jul; 1755(2):135-50. PubMed ID: 15921858
[TBL] [Abstract][Full Text] [Related]
7. Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma.
Kern MA; Haugg AM; Koch AF; Schilling T; Breuhahn K; Walczak H; Fleischer B; Trautwein C; Michalski C; Schulze-Bergkamen H; Friess H; Stremmel W; Krammer PH; Schirmacher P; Müller M
Cancer Res; 2006 Jul; 66(14):7059-66. PubMed ID: 16849551
[TBL] [Abstract][Full Text] [Related]
8. Growth factors as therapeutic targets in HCC.
Furuse J
Crit Rev Oncol Hematol; 2008 Jul; 67(1):8-15. PubMed ID: 18434184
[TBL] [Abstract][Full Text] [Related]
9. Molecular pathogenesis and targeted therapy of hepatocellular carcinoma.
Zender L; Kubicka S
Onkologie; 2008 Oct; 31(10):550-5. PubMed ID: 18854656
[TBL] [Abstract][Full Text] [Related]
10. Attenuation of iNOS in an LPS-stimulated macrophage model by omega-3 fatty acids is independent of COX-2 derived PGE2.
Razzak A; Aldrich C; Babcock TA; Saied A; Espat NJ
J Surg Res; 2008 Apr; 145(2):244-50. PubMed ID: 18067925
[TBL] [Abstract][Full Text] [Related]
11. In-vivo effects and mechanisms of celecoxib-reduced growth of cyclooxygenase-2 (COX-2)-expressing versus COX-2-deleted human HCC xenografts in nude mice.
Cui W; Hu SX; Tang ZY; Hu KQ
Anticancer Drugs; 2008 Oct; 19(9):891-7. PubMed ID: 18766003
[TBL] [Abstract][Full Text] [Related]
12. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
Pang RW; Poon RT
Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
[TBL] [Abstract][Full Text] [Related]
13. Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents.
Chaparro M; González Moreno L; Trapero-Marugán M; Medina J; Moreno-Otero R
Aliment Pharmacol Ther; 2008 Dec; 28(11-12):1269-77. PubMed ID: 18808443
[TBL] [Abstract][Full Text] [Related]
14. The selective cyclooxygenase-1 inhibitor SC-560 suppresses cell proliferation and induces apoptosis in human hepatocellular carcinoma cells.
Lampiasi N; Foderà D; D'Alessandro N; Cusimano A; Azzolina A; Tripodo C; Florena AM; Minervini MI; Notarbartolo M; Montalto G; Cervello M
Int J Mol Med; 2006 Feb; 17(2):245-52. PubMed ID: 16391822
[TBL] [Abstract][Full Text] [Related]
15. The epidermal growth factor receptor: a link between inflammation and liver cancer.
Berasain C; Perugorria MJ; Latasa MU; Castillo J; Goñi S; Santamaría M; Prieto J; Avila MA
Exp Biol Med (Maywood); 2009 Jul; 234(7):713-25. PubMed ID: 19429859
[TBL] [Abstract][Full Text] [Related]
16. Dysregulation of growth factor signaling in human hepatocellular carcinoma.
Breuhahn K; Longerich T; Schirmacher P
Oncogene; 2006 Jun; 25(27):3787-800. PubMed ID: 16799620
[TBL] [Abstract][Full Text] [Related]
17. Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma.
Liu Y; Poon RT; Shao W; Sun X; Chen H; Kok TW; Fan ST
Cancer Lett; 2007 Apr; 248(1):32-40. PubMed ID: 16837130
[TBL] [Abstract][Full Text] [Related]
18. Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities.
Yanase K; Yoshiji H; Ikenaka Y; Noguchi R; Kitade M; Kaji K; Yoshii J; Namisaki T; Yamazaki M; Asada K; Tsujimoto T; Akahane T; Uemura M; Fukui H
Oncol Rep; 2007 Feb; 17(2):441-6. PubMed ID: 17203185
[TBL] [Abstract][Full Text] [Related]
19. Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib.
Xie H; Gao L; Chai N; Song J; Wang J; Song Z; Chen C; Pan Y; Zhao L; Sun S; Wu K; Feitelson MA; Liu J; Fan D
Mol Carcinog; 2009 Jan; 48(1):56-65. PubMed ID: 18506760
[TBL] [Abstract][Full Text] [Related]
20. Systemic therapy for hepatocellular carcinoma.
Thomas MB
Cancer J; 2008; 14(2):123-7. PubMed ID: 18391618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
